Lv2
104 积分 2025-03-18 加入
Time-Dependent Comparative Effectiveness of First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Restricted Mean Survival Time-Based Network Meta-analysis
17天前
已完结
Time-Dependent Comparative Effectiveness of First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Restricted Mean Survival Time-Based Network Meta-analysis
22天前
已完结
Two-phase Intravesical Injection of Apheresis-derived Platelet-rich Plasma for Non-ulcerative Primary Bladder Pain Syndrome: A Prospective Single-center Study
1个月前
已关闭
Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience
1个月前
已关闭
First-line therapies analysis in advanced/metastatic urothelial carcinoma: prognostic insights in ADCs combined therapy with propensity score analysis and RNA-Seq
1个月前
已关闭
Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy
4个月前
已完结
Efficacy and safety of disitamab vedotin in combination with immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
4个月前
已完结
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
4个月前
已完结
RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China
5个月前
已完结
皖公网安备34019202002308
